Effect of Simvastatin on Bone Metabolism in Hypercholesterolic Patients with Osteopenia

DING Yueyou,KANG Bin,JIANG Jiayi,JIANG Shifeng,XU Weiming
DOI: https://doi.org/10.3969/j.issn.1006-7108.2007.12.013
2007-01-01
Abstract:Objective To investigate the short-term effect of simvastatin on the bone metabolism in hypercholesterolic patients with osteopenia.Methods 55 hypercholesterolic patients with osteopenia(mean age 66.8±4.7 years,male 24 and female 31)were enrolled and assigned into two groups randomizedly.One group received simvatatin(20 mg/day),another with diet control.All subjects received 1000mg calcium tablets each day.In all subjects,at baseline and after 6-months serum lipids,bone metabolism markers and BMD were measured.Results After 6-months treatment of simvastatin,total cholesterol and low density lipoprotein cholesterol and(P0.01 for both parameters).Alkaline phosphatase(ALP) and bone gla protein(BGP) did not change significantly.However,urine deoxypyddinoline/creatinine(Dpd/Cr) levels decreased signicantly(6.32±1.36 vs 5.04±1.32,P0.01).Meanwhile,in the control group all metabolic markers did not change significantly.Although there was a tendency of increase of BMD in both lunar spine and femoral bone in the treatment group,none of them reached statistical significance.Conclusion Simvastatin may have potentially beneficial effects on bone metabolism in hypercholesterolic patients with osteopenia mostly by reducing bone resorption rather than by stimulating bone formation.Further studies with more patients and longer duration are necessary to evaluate its effects on prevention of osteoporosis and subsequent fractures.
What problem does this paper attempt to address?